Immunogen Inc. (NASDAQ:IMGN) finished Friday with a subtraction of -$0.13 to close at $15.87, a downside of -0.81 percent. An average of 3,106,380 shares of common stock have been traded in the last five days. There was a gain of $1.10 in the past week, and it reached a new high 24 times over the past 12 months. The last 20 days have seen an average of 3,386,580 shares traded, while the 50-day average volume stands at 4,299,500.
IMGN stock has decreased by -0.38% in the last month. The company shares reached their 1-month lowest point of $14.41 on 09/21/23. With the stock rallying to its 52-week high on 07/19/23, shares of the company touched a low of $3.61 and a high of $20.69 in 52 weeks. It has reached a new high 20 times so far this year and achieved 219.96% or $10.91 in price. In spite of this, the price is down -23.30% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
IMGN stock investors should be aware that Immunogen Inc. (IMGN) stock had its last reported insider trading activity 15 days ago on Sep 15. In this transaction, the insider spent $2,964,681. SVP & CHIEF BUSINESS OFFICER, Coen Stacy Ann, disposed of 100,210 shares at a price of $14.20 on Aug 09. The insider now owns more than $1,422,982 worth of shares. Prior to that, CHIEF EXECUTIVE OFFICER Enyedy Mark J went on to Sale 992,397 shares at $16.96 each on Aug 04. An amount of $16,831,053 was transacted.
Valuation Metrics
Immunogen Inc. (IMGN) stock’s beta is 0.99. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 20.84, the price-to-book (PB) ratio at 8.04.
Financial Health
The quick ratio of Immunogen Inc. for the three months ended June 29 was 7.11, and the current ratio was 7.14, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.20 and a total debt to equity ratio of 0.23 for the quarter ending June 29. Its gross profit as reported stood at $108.61 million compared to revenue of $108.78 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Immunogen Inc.’s return on assets was -32.03%.
Earnings Surprise
For the three-month period that ended June 29, Immunogen Inc. had $71.96 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$4.25 million in the quarter, while revenues were shrunk -1359.29%. The analyst consensus anticipated Immunogen Inc.’s latest quarter earnings to come in at -$0.14 per share, but it turned out to be -$0.02, a 85.70% surprise. For the quarter, EBITDA amounted to -$3.76 million. Shareholders own equity worth $248.94 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Immunogen Inc. (IMGN) price momentum. RSI 9-day as of the close on 29 September was 58.53%, suggesting the stock is Neutral, with historical volatility in this time frame at 47.69%.
As of today, IMGN’s price is $15.37 +7.45% or $1.10 from its 5-day moving average. IMGN is currently trading +0.19% higher than its 20-day SMA and +18.97% higher than its 100-day SMA. However, the stock’s current price level is -16.87% below the SMA50 and +213.02% above the SMA200.
The stochastic %K and %D were 66.50% and 49.11%, respectively, and the average true range (ATR) was 0.57. With the 14-day stochastic at 72.10% and the average true range at 0.61, the RSI (14) stands at 53.31%. The stock has reached 0.55 on the 9-day MACD Oscillator while the 14-day reading was at 0.37.
Analyst Ratings
Piper Sandler upgraded Immunogen Inc. (NASDAQ: IMGN) to a an Overweight rating in its most recent analyst report. Previously, the stock was rated as a Neutral. The consensus rating for Immunogen Inc. (IMGN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell IMGN, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 1 analysts, while 10 others rate it as a “buy”.
What is IMGN’s price target for the next 12 months?
Analysts predict a range of price targets between $13.00 and $27.00, with a median target of $24.50. Taking a look at these predictions, the average price target given by analysts for Immunogen Inc. (IMGN) stock is $23.60.
